Currently up to one‐third of colorectal cancer patients present with locally advanced or
metastatic disease that precludes a surgical cure. Performance limitations and low uptake of …

AIM: To investigate the feasibility of detecting methylated fecal DNA as a screening tool for
colorectal carcinoma (CRC) and precancerous lesions. METHODS: Methylated secreted …

Colorectal cancer (CRC) arises from accumulated genetic and epigenetic alterations, which
provide the possibility to identify tumor-specific biomarkers by analyzing fecal DNA …

Background: Aberrant DNA methylation is more prominent in proximal compared with distal
colorectal cancers. Although a number of methylation markers were identified for colon …

Solid tumors shed DNA into circulation, and there is growing evidence that the detection of
circulating tumor DNA (ctDNA) has broad clinical utility, including monitoring of disease …

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide that is
attributed to gradual long‐term accumulation of both genetic and epigenetic changes. To …

Background & Aims: Detection of tumor-derived DNA alterations in stool is an intriguing new
approach with high potential for the noninvasive detection of colorectal cancer (CRC) …

Aim Improved methods for early detection of colorectal cancer (CRC) are essential for
increasing survival. Hypermethylated DNA in blood or stool has been proposed as a …

DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer (CRC) and
precursor lesions have been extensively studied. Different panels have been reported …

Background Colorectal cancer (CRC) is one of the most common cancers in the western
world. Screening is an efficient method of reducing cancer-related mortality. Molecular …